Archives of Clinical Infectious Diseases

Published by: Kowsar

Lousy Suggestion of Second-Line Therapy Against Helicobacter pylori

Amin Talebi Bezmin Abadi 1 , *
Author Information
1 Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: January 2018, 13 (1); e13770
  • Published Online: January 29, 2018
  • Article Type: Letter
  • Received: July 17, 2016
  • Revised: May 21, 2017
  • Accepted: September 18, 2017
  • DOI: 10.5812/archcid.13770

To Cite: Talebi Bezmin Abadi A. Lousy Suggestion of Second-Line Therapy Against Helicobacter pylori, Arch Clin Infect Dis. 2018 ; 13(1):e13770. doi: 10.5812/archcid.13770.

Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
Footnote
References
  • 1. Shahabimehr M, Alebouyeh M, Farzi N, Mahboubi A, Taslimi R, Zali MR. Resistance rate and minimum inhibitory concentration of metronidazole among helicobacter pylori strains in Tehran, Iran. Arch Clin Infect Dis. 2016;11(2). doi: 10.5812/archcid.34478.
  • 2. Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. 2014;2014:124607. doi: 10.1155/2014/124607. [PubMed: 24800203].
  • 3. Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. J Glob Antimicrob Resist. 2017;8:123-30. doi: 10.1016/j.jgar.2016.11.008. [PubMed: 28131855].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments